Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety

PURPOSE: In this meta-analysis and systemic review, we focused on the effectiveness and safety of anlotinib in patients with advanced non-small cell lung cancer(NSCLC). METHODS: The databases of PubMed, EMBASE, Cochrane Library, CNKI, Wanfang, and CBM were searched by 2 investigators up to April 202...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Haiyong, Li, Zhaoyi, Liu, Kangning, Zhang, Feng, Cheng, Zhengliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202555/
https://www.ncbi.nlm.nih.gov/pubmed/34114981
http://dx.doi.org/10.1097/MD.0000000000025709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202555/
https://www.ncbi.nlm.nih.gov/pubmed/34114981
http://dx.doi.org/10.1097/MD.0000000000025709

Ejemplares similares